Prasugrel, Clopidogrel head-to-head study

A new, pre-specified analysis of the landmark Phase III head-to-head Triton-Timi 38 study showed certain patients were 35% less likely to have a recurrent event (composite endpoint of heart attack, stroke or cardiovascular death) than those who took clopidogrel (10.8% vs. 15.4%; P=0.016).

The patients studied took Prasugrel for acute coronary syndromes (ACS) managed with an artery-opening procedure known as percutaneous coronary intervention (PCI) and had survived their first cardiovascular event and then suffered a subsequent event.

These data appear as a special advance access online publication from the European Heart Journal.

The recurrence of subsequent events assessment was part of the larger Triton-Timi 38 trial, the primary measure of which showed that Prasugrel taken with aspirin reduced the relative risk of the combined endpoint of cardiovascular death, non-fatal heart attacks or non-fatal stroke by 19% more than clopidogrel (Plavix/Iscover) taken with aspirin.